FIRST AMENDMENT TO NOTE DOCUMENTSPuma Biotechnology, Inc. • March 3rd, 2022 • Pharmaceutical preparations • New York
Company FiledMarch 3rd, 2022 Industry JurisdictionThis FIRST AMENDMENT TO NOTE DOCUMENTS (the “Agreement”) dated as of February 8, 2022 is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent. All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Note Purchase Agreement (as defined below).